Metformin monotherapy for type 2 diabetes mellitus (Q24246552)

https://api.crossref.org/works/10.1002%2F14651858.CD002966.PUB3

Improved glycaemic control by addition of glimepiride to metformin monotherapy in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002966.PUB3

Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002966.PUB3

Six-month efficacy of benfluorex vs. placebo or metformin in diet-failed type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002966.PUB3

Double-blind evaluation of efficacy and tolerability of metformin in NIDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002966.PUB3

Metformin's effects on glucose and lipid metabolism in patients with secondary failure to sulfonylureas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002966.PUB3

Multicenter, randomized, double-masked, parallel-group assessment of simultaneous glipizide/metformin as second-line pharmacologic treatment for patients with type 2 diabetes mellitus that is inadequately controlled by a sulfonylurea

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002966.PUB3

The effects of high- and medium-dose metformin therapy on cardiovascular risk factors in patients with type II diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002966.PUB3

Rosiglitazone but not metformin enhances insulin- and exercise-stimulated skeletal muscle glucose uptake in patients with newly diagnosed type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002966.PUB3

Effects of antihyperglycaemic therapies on proinsulin and relation between proinsulin and cardiovascular risk factors in type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002966.PUB3

Antihyperglycaemic efficacy, response prediction and dose-response relations of treatment with metformin and sulphonylurea, alone and in primary combination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002966.PUB3

Efficacy of 24-week monotherapy with acarbose, metformin, or placebo in dietary-treated NIDDM patients: the Essen-II Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002966.PUB3

Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002966.PUB3

Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002966.PUB3

Metformin decreases food consumption and induces weight loss in subjects with obesity with type II non-insulin-dependent diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002966.PUB3

Improved endothelial function with metformin in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002966.PUB3

Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002966.PUB3

Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002966.PUB3

Metabolic and haemodynamic effects of metformin in patients with type 2 diabetes mellitus and hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002966.PUB3

Results of a placebo-controlled study of the metabolic effects of the addition of metformin to sulfonylurea-treated patients. Evidence for a central role of adipose tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002966.PUB3

A comparison of acarbose versus metformin as an adjuvant therapy in sulfonylurea-treated NIDDM patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002966.PUB3

Effect of combination glipizide GITS/metformin on fibrinolytic and metabolic parameters in poorly controlled type 2 diabetic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002966.PUB3

Metabolic and hemodynamic effects of metformin and glibenclamide in normotensive NIDDM patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002966.PUB3

The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002966.PUB3

Regulation of glucose transport and insulin signaling by troglitazone or metformin in adipose tissue of type 2 diabetic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002966.PUB3

Comparison of metformin and chlorpropamide in non-obese, maturity-onset diabetics uncontrolled by diet

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002966.PUB3

Pharmacokinetics and pharmacodynamics of glyburide/metformin tablets (Glucovance) versus equivalent doses of glyburide and metformin in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002966.PUB3

Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002966.PUB3

A comparison of preconstituted, fixed combinations of low-dose glyburide plus metformin versus high-dose glyburide alone in the treatment of type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002966.PUB3

Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002966.PUB3

Intensive insulin therapy combined with metformin in obese type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002966.PUB3

Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002966.PUB3

Durability of efficacy and long-term safety profile of glyburide/metformin tablets in patients with type 2 diabetes mellitus: an open-label extension study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002966.PUB3

Glyburide/metformin combination product is safe and efficacious in patients with type 2 diabetes failing sulphonylurea therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002966.PUB3

Influence of initial hyperglycaemia, weight and age on the blood glucose lowering efficacy and incidence of hypoglycaemic symptoms with a single-tablet metformin-glibenclamide therapy (Glucovance) in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002966.PUB3

Efficacy of glyburide/metformin tablets compared with initial monotherapy in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002966.PUB3

Simultaneous glyburide/metformin therapy is superior to component monotherapy as an initial pharmacological treatment for type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002966.PUB3

Improved glycaemic control with metformin-glibenclamide combined tablet therapy (Glucovance) in Type 2 diabetic patients inadequately controlled on metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002966.PUB3

Metformin for obese, insulin-treated diabetic patients: improvement in glycaemic control and reduction of metabolic risk factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002966.PUB3

The insulin-sparing effect of metformin in insulin-treated diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002966.PUB3

Poorly controlled elderly Type 2 diabetic patients: the effects of increasing sulphonylurea dosages or adding metformin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002966.PUB3

Different effects of insulin and oral antidiabetic agents on glucose and energy metabolism in type 2 (non-insulin-dependent) diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002966.PUB3

Prospective comparative study in NIDDM patients of metformin and glibenclamide with special reference to lipid profiles

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002966.PUB3

Sulphonylurea failure in type 2 diabetes: treatment with a basal insulin supplement.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002966.PUB3

Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002966.PUB3

The impact of metformin therapy on hepatic glucose production and skeletal muscle glycogen synthase activity in overweight type II diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002966.PUB3

Effect of metformin in pediatric patients with type 2 diabetes: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002966.PUB3

Comparison of tolbutamide and metformin in elderly diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002966.PUB3

Acarbose for the treatment of type II diabetes: the results of a Canadian multi-centre trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002966.PUB3

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002966.PUB3

Placebo-controlled trial of the effects of guar gum and metformin on fasting blood glucose and serum lipids in obese, type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002966.PUB3

Causes of weight gain during insulin therapy with and without metformin in patients with Type II diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002966.PUB3

A comparison of treatment with metformin and gliclazide in patients with non-insulin-dependent diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002966.PUB3

The diabetes prevention program and its global implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002966.PUB3

Effect of metformin on intact proinsulin and des 31,32 proinsulin concentrations in subjects with non-insulin-dependent (type 2) diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002966.PUB3

Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002966.PUB3

The influence of dimethylbiguanide on phenprocoumon elimination and its mode of action. A drug interaction study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002966.PUB3

The effects of metformin on adipocyte insulin action and metabolic control in obese subjects with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002966.PUB3

Combined metformin and insulin therapy for patients with type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002966.PUB3

Insulin Receptor Binding to Monocytes, Insulin Secretion, and Glucose Tolerance Following Metformin Treatment: Results of a Double-Blind Cross-Over Study in Type II Diabetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002966.PUB3

The reduction of low density lipoprotein cholesterol by metformin is maintained with long-term therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002966.PUB3

Adding metformin versus insulin dose increase in insulin-treated but poorly controlled Type 2 diabetes mellitus: an open-label randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002966.PUB3

The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002966.PUB3

Effect of metformin on bile salt circulation and intestinal motility in type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002966.PUB3

Leptin and body fat in type 2 diabetes and monodrug therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002966.PUB3

Insulin and sulphonylurea in the therapy of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002966.PUB3

The effect of repaglinide on insulin secretion and oxidative stress in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002966.PUB3

Combination treatment with metformin and glibenclamide versus single-drug therapies in type 2 diabetes mellitus: a randomized, double-blind, comparative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002966.PUB3

Comparison of combined therapies in treatment of secondary failure to glyburide

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002966.PUB3

Efficacy of combined treatments in NIDDM patients with secondary failure to sulphonylureas. Is it predictable?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002966.PUB3

A comparison of metformin versus guar in combination with sulphonylureas in the treatment of non insulin dependent diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002966.PUB3

The effect of a thiazolidinedione drug, troglitazone, on glycemia in patients with type 2 diabetes mellitus poorly controlled with sulfonylurea and metformin. A multicenter, randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002966.PUB3

Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002966.PUB3

A comparison of troglitazone and metformin on insulin requirements in euglycemic intensively insulin-treated type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002966.PUB3

Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002966.PUB3

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002966.PUB3

Operating characteristics of a rank correlation test for publication bias

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002966.PUB3

The synergistic effect of miglitol plus metformin combination therapy in the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002966.PUB3

How study design affects outcomes in comparisons of therapy. I: Medical

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002966.PUB3

Pharmacologic therapy for type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002966.PUB3

Identifying relevant studies for systematic reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002966.PUB3

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002966.PUB3

Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002966.PUB3

Quantifying heterogeneity in a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002966.PUB3

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002966.PUB3

Efficacy of metformin in the treatment of NIDDM. Meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002966.PUB3

UK's diagnostic criteria for diabetes are different from US's

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002966.PUB3

Seeing what you want to see in randomised controlled trials: versions and perversions of UKPDS data. United Kingdom prospective diabetes study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002966.PUB3

Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002966.PUB3

The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002966.PUB3

Surrogate end points, health outcomes, and the drug-approval process for the treatment of risk factors for cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002966.PUB3

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002966.PUB3

What happened to the valid POEMs? A survey of review articles on the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002966.PUB3

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002966.PUB3

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002966.PUB3

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002966.PUB3

Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002966.PUB3

Oral antidiabetic treatment in patients with coronary disease: time-related increased mortality on combined glyburide/metformin therapy over a 7.7-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002966.PUB3

7 January 2021

Worldwide experience of metformin as an effective glucose-lowering agent: a meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002966.PUB3

7 January 2021

Metformin-induced changes in serum lipids, lipoproteins, and apoproteins in non-insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002966.PUB3

7 January 2021

Effects of gliclazide versus metformin on the clinical profile and lipid peroxidation markers in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002966.PUB3

7 January 2021

Some answers, more controversy, from UKPDS. United Kingdom Prospective Diabetes Study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002966.PUB3

7 January 2021

Comparison of acarbose and metformin in patients with Type 2 diabetes mellitus insufficiently controlled with diet and sulphonylureas: a randomized, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002966.PUB3

7 January 2021

Therapeutic effect of glibenclamide in a fixed combination with metformin or phenformin in NIDDM patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002966.PUB3

7 January 2021

The effect of glibenclamide and metformin on serum lipoproteins in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002966.PUB3

7 January 2021

Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. National Diabetes Data Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002966.PUB3

7 January 2021

Comparative effects of glibenclamide and metformin on ambulatory blood pressure and cardiovascular reactivity in NIDDM

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002966.PUB3

7 January 2021

Irreversibility of the defect in glycogen synthase activity in skeletal muscle from obese patients with NIDDM treated with diet and metformin

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002966.PUB3

7 January 2021

Metformin added to insulin therapy in poorly controlled type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002966.PUB3

7 January 2021

Effects of metformin in patients with poorly controlled, insulin-treated type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002966.PUB3

7 January 2021